Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Positive Top-Line Data Out for Shionogi’s Sakigake-Designated Flu Med
Top-line PIII data show that Shionogi’s investigational anti-influenza drug S-033188, which is designated for the sakigake fast-track pathway in Japan, significantly shortened time to the improvement of major flu symptoms versus placebo, the company said on July 24. The PIII…
To read the full story
Related Article
- Shionogi’s Sakigake-Designated Flu Med Filed in Japan
October 26, 2017
- Shionogi to File Sakigake-Designated Flu Drug by Year-End Based on PIII Results
September 15, 2017
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Med Shows Efficacy in Japan PII
August 30, 2016
BUSINESS
- FRONTEO, Daiichi Sankyo Build AI Model to Analyze Toxicity Reports
July 15, 2026
- Cell Resources Launches Umbilical Cord- and Amnion-Derived MSCs
July 15, 2026
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
- FDA Greenlights Leqembi Iqlik for Alzheimer’s Initiation Therapy
July 14, 2026
- Santen, Kyorin Strike Co-Promotion Deal for Alesion Eyelid Cream
July 14, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…